Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), effective January 1, 2024. In this role, Dr. Pitukcheewanont will provide his leadership in Lumos Pharma’s efforts to hone its clinical and regulatory strategy, and he will continue to oversee medical affairs as the Company prepares to initiate its pivotal Phase 3 trial evaluating the efficacy of oral LUM-201 in treating moderate pediatric growth hormone deficiency (PGHD).
Related news for (LUMO)
- Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
- 24/7 Market News Snapshot 23 October, 2024 – Lumos Pharma, Inc. Common Stock (NASDAQ:LUMO)
- lumos pharma enters into definitive merger agreement with double point ventures to go private via a tender offer of $4.25 cash per share plus contingent value rights (cvr)
- Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference